Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company focused on developing innovative cancer therapies, announced that its CEO and Chairman, Dr. Vuong Trieu, will present at the OTCQB Virtual Investor Conference on August 6, 2026, at 2:30 p.m. ET. The presentation will include a live question-and-answer session, providing investors with an opportunity to engage directly with the company's leadership. This announcement comes as Oncotelic continues to make significant strides in its clinical programs and technological platforms, underscoring its commitment to advancing precision medicine and AI-driven drug discovery.
The company will highlight several key developments during the conference, including the progression of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort. This advancement marks a critical step in the clinical evaluation of Sapu003, a novel formulation of everolimus designed to improve delivery and efficacy. Additionally, Oncotelic has expanded its European clinical sites, which is expected to accelerate patient recruitment and broaden the trial's reach. These milestones reflect the company's dedication to bringing potentially life-saving therapies to patients with cancer and other serious diseases.
Oncotelic will also showcase the validation of its Deciparticle platform through peer-reviewed publications. The Deciparticle technology is a proprietary drug delivery system that enhances the bioavailability and targeting of therapeutic agents, potentially improving patient outcomes while reducing side effects. The company's scalable cGMP manufacturing capabilities will be another focal point, ensuring that as therapies advance through clinical trials, they can be produced reliably and at scale to meet future demand.
Furthermore, the presentation will cover Oncotelic's continued development of AI-driven drug discovery, robotics, and nanomedicine platforms. These cutting-edge technologies are designed to accelerate the identification of new therapeutic candidates and optimize their development, positioning Oncotelic at the forefront of the biotech industry's digital transformation. By integrating artificial intelligence with advanced nanomedicine, the company aims to reduce the time and cost associated with bringing new drugs to market, ultimately benefiting patients worldwide.
The significance of this announcement lies in the potential impact on the biotechnology sector and the broader healthcare landscape. For investors, the conference offers a transparent view of Oncotelic's progress and future direction, which could influence investment decisions. For the industry, Oncotelic's advancements in AI and nanomedicine highlight the growing trend toward personalized medicine and the use of technology to enhance drug development efficiency. As the company continues to advance its pipeline, the outcomes of its clinical trials and platform validations may have far-reaching implications for cancer treatment and beyond.
Investors and interested parties can access the full press release at https://nnw.fm/fGHUt. For the latest news and updates regarding Oncotelic Therapeutics, visit the company's newsroom at https://nnw.fm/OTLC.
